Duncan Armour
Publications by Year
Research Areas
Neuropeptides and Animal Physiology, Receptor Mechanisms and Signaling, HIV Research and Treatment, HIV/AIDS drug development and treatment, Chemical Synthesis and Analysis
Most-Cited Works
- → Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity(2005)1,144 cited
- → The Discovery of the CCR5 Receptor Antagonist, UK-427,857, A New Agent for the Treatment of HIV Infection and AIDS(2005)161 cited
- → GR205171: A novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity(1996)145 cited
- → Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity. 1. Optimization of the Agonist “Trigger”(1996)101 cited
- → Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc(2006)76 cited
- → Enantioselective Synthesis of 3,6-Dihydro-1H-pyridin-2-ones: Unexpected Regioselectivity in the Palladium-Catalyzed Decarboxylative Carbonylation of 5-Vinyloxazolidin-2-ones(2000)73 cited
- → Discovery of an Orally Bioavailable NK1 Receptor Antagonist, (2S,3S)-(2-Methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with Potent Antiemetic Activity(1995)52 cited
- → Tetrazole NK1 receptor antagonists: The identification of an exceptionally potent orally active antiemetic compound(1996)43 cited
- → The Discovery of CCR5 Receptor Antagonists for the Treatment of HIV Infection: Hit‐to‐Lead Studies(2006)29 cited
- → Overcoming hERG Affinity in the Discovery of Maraviroc; A CCR5 Antagonist for the Treatment of HIV(2008)22 cited